Literature DB >> 29164656

Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.

Roland B Walter1,2, Laura C Michaelis3, Megan Othus4, Geoffrey L Uy5, Jerald P Radich1,2, Richard F Little6, Sandi Hita7, Lalit Saini8, James M Foran9, Aaron T Gerds10, Heidi D Klepin11, Annette E Hay12, Sarit Assouline13, Jeffrey E Lancet14, Stephen Couban15, Mark R Litzow16, Richard M Stone17, Harry P Erba18.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29164656      PMCID： PMC5760282          DOI： 10.1002/ajh.24980

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  13 in total

1.  Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI.

Authors:  Megan Othus; Wim van Putten; Bob Lowenberg; Stephen H Petersdorf; Sucha Nand; Harry Erba; Frederick Appelbaum; Robert Hills; Nigel Russell; Alan Burnett; Elihu Estey
Journal:  Haematologica       Date:  2016-03-24       Impact factor: 9.941

2.  Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.

Authors:  Alan K Burnett; Nigel H Russell; Ann E Hunter; Donald Milligan; Steven Knapper; Keith Wheatley; John Yin; Mary F McMullin; Sahra Ali; David Bowen; Robert K Hills
Journal:  Blood       Date:  2013-07-09       Impact factor: 22.113

3.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Authors:  Hagop M Kantarjian; Xavier G Thomas; Anna Dmoszynska; Agnieszka Wierzbowska; Grzegorz Mazur; Jiri Mayer; Jyh-Pyng Gau; Wen-Chien Chou; Rena Buckstein; Jaroslav Cermak; Ching-Yuan Kuo; Albert Oriol; Farhad Ravandi; Stefan Faderl; Jacques Delaunay; Daniel Lysák; Mark Minden; Christopher Arthur
Journal:  J Clin Oncol       Date:  2012-06-11       Impact factor: 44.544

4.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

Authors:  Hervé Dombret; John F Seymour; Aleksandra Butrym; Agnieszka Wierzbowska; Dominik Selleslag; Jun Ho Jang; Rajat Kumar; James Cavenagh; Andre C Schuh; Anna Candoni; Christian Récher; Irwindeep Sandhu; Teresa Bernal del Castillo; Haifa Kathrin Al-Ali; Giovanni Martinelli; Jose Falantes; Richard Noppeney; Richard M Stone; Mark D Minden; Heidi McIntyre; Steve Songer; Lela M Lucy; C L Beach; Hartmut Döhner
Journal:  Blood       Date:  2015-05-18       Impact factor: 22.113

5.  The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison.

Authors:  A K Burnett; R K Hills; A E Hunter; D Milligan; W J Kell; K Wheatley; J Yin; M F McMullin; H Dignum; D Bowen; N H Russell
Journal:  Leukemia       Date:  2012-08-14       Impact factor: 11.528

Review 6.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

Review 7.  Management of older or unfit patients with acute myeloid leukemia.

Authors:  R B Walter; E H Estey
Journal:  Leukemia       Date:  2014-07-09       Impact factor: 11.528

Review 8.  Emerging innovations in clinical trial design.

Authors:  D A Berry
Journal:  Clin Pharmacol Ther       Date:  2015-11-19       Impact factor: 6.875

Review 9.  Acute myeloid leukemia and myelodysplastic syndromes in older adults.

Authors:  Heidi D Klepin; Arati V Rao; Timothy S Pardee
Journal:  J Clin Oncol       Date:  2014-08-20       Impact factor: 44.544

10.  A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.

Authors:  Alan K Burnett; Donald Milligan; Archie G Prentice; Anthony H Goldstone; Mary F McMullin; Robert K Hills; Keith Wheatley
Journal:  Cancer       Date:  2007-03-15       Impact factor: 6.860
View more
  5 in total

Review 1.  Older adults with cancer and their caregivers - current landscape and future directions for clinical care.

Authors:  Sindhuja Kadambi; Kah Poh Loh; Richard Dunne; Allison Magnuson; Ronald Maggiore; Jason Zittel; Marie Flannery; Julia Inglis; Nikesha Gilmore; Mostafa Mohamed; Erika Ramsdale; Supriya Mohile
Journal:  Nat Rev Clin Oncol       Date:  2020-09-02       Impact factor: 66.675

Review 2.  Geriatric Assessment in Older Patients with Acute Myeloid Leukemia.

Authors:  Kah Poh Loh; Heidi D Klepin
Journal:  Cancers (Basel)       Date:  2018-07-06       Impact factor: 6.639

3.  Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols.

Authors:  Jay J H Park; Ellie Siden; Michael J Zoratti; Louis Dron; Ofir Harari; Joel Singer; Richard T Lester; Kristian Thorlund; Edward J Mills
Journal:  Trials       Date:  2019-09-18       Impact factor: 2.279

4.  Reporting of master protocols towards a standardized approach: A systematic review.

Authors:  Ellie G Siden; Jay Jh Park; Michael J Zoratti; Louis Dron; Ofir Harari; Kristian Thorlund; Edward J Mills
Journal:  Contemp Clin Trials Commun       Date:  2019-07-04

5.  Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials.

Authors:  Helen Mossop; Michael J Grayling; Ferdia A Gallagher; Sarah J Welsh; Grant D Stewart; James M S Wason
Journal:  Br J Cancer       Date:  2021-11-08       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.